Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Analyst picks & changes

Centocor Inc.

(CNTO)

Peter Drake of Vector Securities International reiterated a "buy" on the Malvern, Penn., company. With potentially positive data coming from

Read the full 240 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE